[Fluconazole treatment of systemic mycoses].
Efficacies of fluconazole, a new triazole antifungal agent, were evaluated in 11 cases of systemic mycoses (1 case each of candiduria, pulmonary cryptococcosis, pulmonary aspergillosis, pulmonary penicilliosis and suspected fungal pulmonary infection, and 3 cases each of candidemia and Candida endophthalmitis). The clinical efficacies were excellent or good in 8 out of 9 cases and poor in 1. Side effects observed were mild with 1 incident each of gastrointestinal symptom and reversible leukopenia. This drug appears to be promising in treatment of systemic mycoses.
Mori
T
T
Department of Internal Medicine, Juntendo University School of Medicine.
Matsumura
M
M
Ebe
T
T
Takahashi
M
M
Kohara
T
T
Inagaki
M
M
Isonuma
H
H
Hibiya
I
I
Hamamoto
T
T
Watanabe
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D000855:Anorexia / Q000139:chemically induced; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy; D004341:Drug Evaluation; D004361:Drug Tolerance; D009877:Endophthalmitis / Q000188:drug therapy; D005260:Female; D015725:Fluconazole; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008172:Lung Diseases, Fungal / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy*; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; D015725:Fluconazole